文献速递消化道肿瘤放疗胸部肿瘤放疗

不可手术食管癌同步放化疗中高剂量与标准剂量放疗对比:系统综述与荟萃分析

High-dose versus standard-dose radiotherapy in concurrent chemoradiotherapy for inoperable esophageal cancer: A systematic review and meta-analysis.
PubMed 文献 · Radiother Oncol · 2023-05-09

该系统综述与荟萃分析纳入10项对照研究共4625例不可手术食管癌患者,比较同步放化疗中高剂量放疗(≥60 Gy)与标准剂量放疗(50-50.4 Gy)的疗效与安全性。总人群高剂量组总生存(HR=0.88,95%CI 0.74-1.05,P=0.16)和无进展生存(HR=0.84,95%CI 0.67-1.04,P=0.12)均无显著获益,但食管鳞癌亚组高剂量组总生存更优(HR=0.78,95%CI 0.70-0.88,P<0.0001)。

要点

  • 总食管癌人群中高剂量放疗(≥60 Gy)较标准剂量(50-50.4 Gy)未显著改善总生存(HR=0.88,95%CI 0.74-1.05,P=0.16)。
  • 总食管癌人群中高剂量放疗未显著改善无进展生存(HR=0.84,95%CI 0.67-1.04,P=0.12)。
  • 食管鳞癌亚组中高剂量放疗总生存优于标准剂量组(HR=0.78,95%CI 0.70-0.88,P<0.0001)。

核心结论

  • 与50-50.4 Gy相比,提高放疗剂量至≥60 Gy在不可手术食管癌同步放化疗患者中未取得生存获益。
  • 在食管鳞癌患者中,高剂量(≥60 Gy)放疗可能改善总生存。

研究设计与样本

  • 系统检索PubMed、Web of Science、EMBASE和Cochrane Library数据库截至2022年10月7日的文献,收集食管癌同步放化疗中高剂量(≥60 Gy)与标准剂量(50-50.4 Gy)放疗的对照临床研究。
  • 共纳入10项研究、4625例患者,其中3667例(79.3%)为食管鳞状细胞癌。
  • 研究间无显著异质性时采用固定效应模型合并HR和OR,否则采用随机效应模型。

主要发现

  • 总食管癌人群中,高剂量组与标准剂量组相比总生存无显著获益(HR=0.88,95%CI 0.74-1.05,P=0.16)。
  • 总食管癌人群中,高剂量组与标准剂量组相比无进展生存无显著获益(HR=0.84,95%CI 0.67-1.04,P=0.12)。
  • 食管鳞癌亚组分析中,高剂量组总生存优于标准剂量组(HR=0.78,95%CI 0.70-0.88,P<0.0001)。

关键数值与推荐

  • 高剂量放疗定义为≥60 Gy,标准剂量放疗定义为50-50.4 Gy。
  • 总食管癌人群总生存HR=0.88(95%CI 0.74-1.05,P=0.16)。
  • 总食管癌人群无进展生存HR=0.84(95%CI 0.67-1.04,P=0.12)。
  • 食管鳞癌亚组总生存HR=0.78(95%CI 0.70-0.88,P<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to evaluate the effectiveness and safety of high-dose (HD-RT) versus standard-dose radiotherapy (SD-RT) in concurrent chemoradiotherapy (CCRT) for inoperable esophageal cancer (EC) patients. METHODS: A systematic search of the literature was conducted by screening PubMed, Web of Science, EMBASE and Cochrane Library databases before October 7, 2022 to collect controlled clinical studies of high-dose (≥60 Gy) and standard-dose (50-50.4 Gy) radiation in CCRT for EC. For statistical analysis, a fixed-effects model was used to synthesize HR and OR if there was no significant heterogeneity among studies; otherwise, a random-effects model was employed. RESULTS: There were ten studies with 4625 patients included in the study, 3667 of whom (79.3%) were esophageal squamous cell carcinoma (ESCC). The HD-RT group had no significant benefits in overall survival (OS) (HR = 0.88, 95% confidence interval [CI] = 0.74-1.05, P = 0.16) and progression-free survival (HR = 0.84, 95%CI = 0.67-1.04, P = 0.12) in total EC patients, compared with SD-RT group. However, in ESCC subgroup analysis, compared with SD-RT group, a better OS was observed in the HD-RT group (HR = 0.78, 95%CI = 0.70-0.88, P < 0.0001). CONCLUSION: Compared with the radiation dose of 50-50.4 Gy, the increase of radiation dose (≥60 Gy) did not achieve benefits in survival for inoperable EC patients receiving CCRT. However, in patients with ESCC, high dose (≥60 Gy) of radiation probably improved OS.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yao Y, Lu J, Qin Z, et al. High-dose versus standard-dose radiotherapy in concurrent chemoradiotherapy for inoperable esophageal cancer: A systematic review and meta-analysis. Radiother Oncol. 2023. PMID: 37169302. doi:10.1016/j.radonc.2023.109700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。